Responses to Inhibitory Tumor Antigens, Inhibigens, Suppress Anti-Tumor Immunity & Promote Tumor Growth

Time: 12:30 pm
day: Day One

Details:

• ATLASTM, Genocea’s T cell antigen discovery platform, uniquely identifies surface-presented antigens of anti-tumor T cell responses and antigens of pro-tumor responses (InhibigensTM).
• Inhibigens may be a novel tumor resistance mechanism that generate deleterious, tolerizing immune responses against cancer and should be avoided from vaccines and immunotherapies.
• Inhibigens are found in most cancer patients and the ratio of
• Inhibigens to neoantigens appears to predict checkpoint inhibitor (CPI) immunotherapy outcomes